Vienna Oncology Research Center
Research and Development
Vienna Oncology Center opens
Group photo Inauguration of the Angelika Ammon Laboratory in Vienna The sustainable laboratory building, built at a cost of €60 million, provides modern office and laboratory space. Over the past five years, Boehringer’s capital investments have reached €6 billion.
Boehringer Ingelheim is one of the world’s leading research-driven pharmaceutical companies. The clinical pipeline is continuously developing and Boehringer Ingelheim expects further approvals in the field of oncology over the coming years.
An important investment for the future is the new Angelika Ammon Research Building, which was opened on 25 September in the presence of guests from political and scientific communities. The modern and sustainable building spans 11 floors and provides ideal conditions for researchers. Here, 150 people work on promising treatments against cancer in an environment equipped with state-of-the-art research facilities. The building is named after the internationally renowned Viennese cancer researcher Angelika Ammon (1967-2020), who had close ties to Boehringer Ingelheim. The investment, worth around 60 million euros, is another testament to Boehringer Ingelheim’s commitment to cancer research.
But the completion of the new laboratory building is just one investment among many: last year Boehringer announced a five-year plan that included €7 billion in capital expenditures to support the company’s growth. Under this program, capital expenditures will reach €1.2 billion in 2023. Over the past five years, Boehringer’s capital expenditures have reached €6 billion.
Hope in the fight against cancer
R&D investments in human medicines will increase to €5.8 billion in 2023, accounting for around 25% of net sales of human medicines, ranking Boehringer Ingelheim as one of the top R&D investors in the industry. “Our goal is to further improve human and animal health,” says Paola Casarosa, head of the Innovation Unit, explaining the company’s focus on a promising and broad portfolio in the fight against cancer. “There is still a huge unmet medical need, especially in the field of oncology. We are working with great enthusiasm to make cancer a treatable disease.”
“Our stated goal is to cure cancer. The big challenge is that cancer is not a single disease but a collection of different diseases in different organs. In future, around one third of Boehringer Ingelheim’s new products will come from oncology,” says Norbert Krauth, global head of cancer research.
New High Tech Facility
The latest technology and laboratories will enable scientists to reach their goal of developing innovative treatments for cancer patients faster. With a total floor area of approximately 11,000 square meters, the new building is also at the forefront in terms of sustainability: Photovoltaic arrays on the roof and façade of the 38-meter-tall building will reduce 45 tonnes of CO2 per year. Electrochromic glass darkens automatically in sunlight, reducing the need for cooling by 30 percent.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company committed to both human and animal health. As a leading investor in research and development, the company focuses on developing innovative therapies in areas of unmet medical need. Independent since 1885, Boehringer takes a long-term perspective and embeds sustainability throughout its value chain. More than 53,500 employees are active in more than 130 markets, building a healthier, sustainable and fairer future. For more information, please visit https://www.boehringer-ingelheim.com.
Information for the target audience
This press release is issued from our headquarters in Ingelheim, Germany and is intended to provide information about our global operations. Please note that information regarding approval status and approved product labeling may vary by country, and that country-specific press releases on this topic may have been issued in the countries in which we operate.
References
New Research Building: Accelerating Innovation in Oncology | Boehringer Ingelheim (boehringer-ingelheim.com)
Vienna Oncology Research Center Vienna Oncology Center opened
